ABSTRACT
<p><b>OBJECTIVE</b>To analyze diagnostic value of Copenhagen Index based on pretreatment serum CA125, HE4 and age in differentiating benign and malignant epithelial ovarian tumors.</p><p><b>METHODS</b>The clinical data were analyzed for 208 consecutive patients with epithelial ovarian tumors (including 100 with malignant and 108 with benign tumors) treated in our department between September, 2014 and September, 2016. The receiver-operating characteristic curve was drawn based on the golden standard of pathological diagnosis for calculation of the diagnostic sensitivity and specificity of CA125, HE4 and the Copenhagen Index.</p><p><b>RESULTS</b>In the overall cases, early stage cases and advanced stage cases, the prediction probabilities of CA125, HE4 and Copenhagen Index were all significantly higher for malignant than in benign tumors (P<0.001). The sensitivities of CA125, HE4, Copenhagen Index for differentiating benign and malignant tumors were 81.0%, 86.0% and 91.0% in the overall cases, 64.0%, 68.0% and 72.0% in early stage cases, and 86.7%, 92.0% and 97.3% in advanced stage cases, and their diagnostic specificities were 88.0%, 93.5% and 96.3%, respectively. Copenhagen Index had the highest diagnostic sensitivity (but not in early stage cases) and specificity followed by HE4 and then by CA125 (P<0.001) (P>0.05).</p><p><b>CONCLUSION</b>Copenhagen Index combined with CA125, HE4 and age hase better diagnostic value than HE4 or CA125 alone for differentiation between benign and malignant epithelial ovarian tumors, and can be used clinically to improve the early diagnostic rate of epithelial ovarian cancer.</p>
ABSTRACT
OBJECTIVE: In those patients by monitoring and analyzing the whole blood concentrations of sirolimus of 410 cases of patients underwent kidney transplant, To provide guidance for the reasonable utilization of medications. METHODS: Chemiluminescence microparticles immuno assay (CMIA) was used to determine the whole blood concentrations of sirolimus of 42 patients (410 cases) in the First Affiliated Hospital of Zhengzhou University hospital, from January 2013 to March 2015 years. Then the relationships between the whole blood concentrations of sirolimus and ALT, AST, T-CHO, TG or platelet count were analyzed. RESULTS: In our study, the average whole blood concentration of sirolimus of 410 cases was (5.6±2.9) ng·mL-1, ranging from 1.02 to 22.85 ng·mL-1. Three hundred and six cases got concentrations of 4~8 ng·mL-1, accounted for 74.6%. 46 cases(11.2%)got concentrations less than 4 ng·mL-1 and 58 cases with concentrations more than 8 ng·mL-1 accounted for 14.2%. The whole blood concentration of sirolimus of those patients showed positive correlations with ALT, AST, T-CHO, TG(P <0.05) and negative correlation with platelet count(r=-0.231, P<0.05). Patients with abnormal blood drug concentration may be related to compliance, diet, blood volume, genotype, combination and individual differences. CONCLUSION: With a narrow therapeutic window, individualized dosage regimens need to be adopted and the blood concentration of which should be monitored when sirolimus was used. Close attention should be paid to the concentration of blood fat, and the blood concrentration of sirolimus need timely adjustment to guarantee a considerable efficacy and reduce the incidence of adverse reactions.